Ann Pediatr Endocrinol Metab.  2022 Mar;27(1):22-29. 10.6065/apem.2142144.072.

Genotype-phenotype correlations and long-term efficacy of pamidronate therapy in patients with osteogenesis imperfecta

• Choi Y
• Hwang S
• Kim GH
• Lee BH
• Yoo HW
• Choi JH

• KMID: 2528194
• DOI: http://doi.org/10.6065/apem.2142144.072

Abstract

Purpose
Osteogenesis imperfecta (OI) is a rare bone fragility disorder caused by defects in type 1 collagen biosynthesis. This study investigated the genotype-phenotype correlations and the efficacy of pamidronate therapy in patients with OI in a single academic center.
Methods
This study included 24 patients with OI. A clinical scoring system was used to evaluate disorder severity. COL1A1 and COL1A2 genes were analyzed in 13 patients using Sanger sequencing. Genotype-phenotype correlations and the efficacy of pamidronate therapy were analyzed through a retrospective medical chart review.
Results
Of the 24 patients, 18 (75%) were classified as type I (12 with type Ia and 6 with type Ib), 2 as type III (8.4%), and 4 as type IV (16.7%). Type Ia patients showed relatively higher lumbar bone mineral density (BMD) standard deviation scores (SDS) and lower clinical scores than those with other types. Seven patients with qualitative mutations had lower lumbar BMD-SDS (P=0.015) and higher clinical scores (P=0.008) than 6 patients with quantitative mutations. The annual fracture frequency and lumbar BMD-SDS improved in patients with qualitative mutations after pamidronate treatment.
Conclusion
This study demonstrated that OI patients with qualitative mutations in COL1A1/2 had a more severe phenotype than those with quantitative mutations. Patients with qualitative mutations showed a significant reduction in fracture frequency and an increase in lumbar BMD-SDS after pamidronate treatment. Clinical score and genotype might be helpful for predicting phenotype and response to pamidronate therapy in OI patients.

Keyword

Osteogenesis imperfecta; Pamidronate; Quantitative mutation; Qualitative mutation

Reference

References

1. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011; 7:540–57.

2. Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016; 387:1657–71.

3. Sillence DO, Rimoin DL. Classification of osteogenesis imperfect. Lancet. 1978; 1:1041–2.

4. Chetty M, Roomaney IA, Beighton P. The evolution of the nosology of osteogenesis imperfecta. Clin Genet. 2021; 99:42–52.

5. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010; 53:1–5.

6. Aglan MS, Hosny L, El-Houssini R, Abdelhadi S, Salem F, Elbanna RA, et al. A scoring system for the assessment of clinical severity in osteogenesis imperfecta. J Child Orthop. 2012; 6:29–35.

7. Schleit J, Bailey SS, Tran T, Chen D, Stowers S, Schwarze U, et al. Molecular outcome, prediction, and clinical consequences of splice variants in COL1A1, which encodes the proα1 (I) chains of type I procollagen. Hum Mutat. 2015; 36:728–39.

8. Tournis S, Dede AD. Osteogenesis imperfecta - a clinical update. Metabolism. 2018; 80:27–37.

9. Rauch F, Lalic L, Roughley P, Glorieux FH. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res. 2010; 25:1367–74.

10. Morello R, Bertin TK, Chen YQ, Hicks J, Tonachini L, Monticone M, et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006; 127:291–304.

11. Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S, et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet. 2010; 86:389–98.

12. Martinez-Glez V, Valencia M, Caparros-Martin JA, Aglan M, Temtamy S, Tenorio J, et al. Identification of a mutation causing deficient BMP1/MTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum Mutat. 2012; 33:343–50.

13. Puig-Hervas MT, Temtamy S, Aglan M, Valencia M, Martinez-Glez V, Ballesta-Martinez MJ, et al. Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome-osteogenesis imperfecta phenotypic spectrum. Hum Mutat. 2012; 33:1444–49.

14. Kelley BP, Malfait F, Bonafe L, Baldridge D, Homan E, Symoens S, et al. Mutations in FKBP10 cause recessive osteogenesis imperfecta and bruck syndrome. J Bone Miner Res. 2011; 26:666–72.

15. Laine CM, Joeng KS, Campeau PM, Kiviranta R, Tarkkonen K, Grover M, et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med. 2013; 368:1809–16.

16. Cho SY, Lee JH, Ki CS, Chang MS, Jin DK, Han HS. Osteogenesis imperfecta type I caused by a novel mutation in the start codon of the COL1A1 gene in a Korean family. Ann Clin Lab Sci. 2015; 45:100–5.

17. Choi JH, Shin YL, Yoo HW. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta. J Korean Med Sci. 2007; 22:209–12.

18. Kim JH, Yun S, Hwang SS, Shim JO, Chae HW, Lee YJ, et al. The 2017 Korean national growth charts for children and adolescents: development, improvement, and prospects. Korean J Pediatr. 2018; 61:135–49.

19. Kang MJ, Hong HS, Chung SJ, Lee YA, Shin CH, Yang SW. Body composition and bone density reference data for Korean children, adolescents, and young adults according to age and sex: Results of the 2009-2010 Korean national health and nutrition examination survey (KNHANES). J Bone Miner Metab. 2016; 34:429–39.

20. Lee SH, Desai SS, Shetty G, Song HR, Lee SH, Hur CY, et al. Bone mineral density of proximal femur and spine in Korean children between 2 and 18 years of age. J Bone Miner Metab. 2007; 25:423–30.

21. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002; 86:356–64.

22. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015; 17:405–24.

23. Liu Y, Ma D, Lv F, Xu X, Wang J, et al. Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing. Osteoporos Int. 2017; 28:2985–95.

24. Peng H, Zhang Y, Long Z, Zhao D, Guo Z, Xue J, et al. A novel splicing mutation in COL1A1 gene caused type I osteogenesis imperfecta in a Chinese family. Gene. 2012; 502:168–71.

25. Zhytnik L, Maasalu K, Pashenkos A, Khmyzovs S, Reimann E, Prans E, et al. COL1A1/2 pathogenic variants and phenotype characteristics in Ukrainian osteogenesis imperfecta patients. Front Genet. 2019; 10:722.

26. Maioli M, Gnoli M, Boarini M, Tremosini M, Zambrano A, Pedrini E, et al. Genotype-phenotype correlation study in 364 osteogenesis imperfecta Italian patients. Eur J Hum Genet. 2019; 27:1090–100.

27. Mrosk J, Bhavani GS, Shah H, Hecht J, Kruger U, Shukla A, et al. Diagnostic strategies and genotype-phenotype correlation in a large Indian cohort of osteogenesis imperfecta. Bone. 2018; 110:368–77.

28. Lindahl K, Åström E, Rubin CJ, Grigelioniene G, Malmgren B, Ljunggren Ö, et al. Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet. 2015; 23:1042–50.

29. Andersson K, Dahllof G, Lindahl K, Kindmark A, Grigelioniene G, Astrom E, et al. Mutations in COL1A1 and COL1A2 and dental aberrations in children and adolescents with osteogenesis imperfecta - a retrospective cohort study. PLoS One. 2017; 12:e0176466.

30. Lund AM, Jensen BL, Nielsen LA, Skovby F. Dental manifestations of osteogenesis imperfecta and abnormalities of collagen I metabolism. J Craniofac Genet Dev Biol. 1998; 18:30–37.

31. Rauch F, Lalic L, Roughley P, Glorieux FH. Genotype-phenotyp e correl ations in non let ha l oste ogenesis imperfecta caused by mutations in the helical domain of collagen type I. Eur J Hum Genet. 2010; 18:642–47.

32. Thuesen KJ, Gjorup H, Hald JD, Schmidt M, Harslof T, Langdahl B, et al. The dental perspective on osteogenesis imperfecta in a Danish adult population. BMC Oral Health. 2018; 18:175.

33. Morello R. Osteogenesis imperfecta and therapeutics. Matrix Biol. 2018; 71-72:294–312.

34. Sato A, Ouellet J, Muneta T, Glorieux FH, Rauch F. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment. Bone. 2016; 86:53–57.

35. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016; 10:CD005088.

36. Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Soderhall S, et al. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I,III and IV treated with pamidronate. Bone. 2016; 87:11–8.

37. Cho TJ, Park MS, Choi IH, Chung CY, Yoo WJ. Efficacy of cyclic intravenous pamidronate therapy for children with osteogenesis imperfecta. J Korean Orthop Assoc. 2003; 38:741–47.

38. Lee SW, Kim HJ, Cho JH, Lee HS, Jung YM, Kim DJ, et al. Effects of pamidronate treatment on osteogenesis imperfecta. J Korean Soc Endocrinol. 2004; 19:485–91.

39. Yi KH, Hwang JS, Kim EY, Lee JA, Kim DH, Lim JS. Reference values for bone mineral density according to age with body size adjustment in Korean children and adolescents. J Bone Miner Metab. 2014; 32:281–89.